Ulcerative Colitis Drug Shows Remission Gains

OD-001 improved clinical remission in moderately to severely active ulcerative colitis in a phase 2a trial, and it is advancing to phase 2b.

Updated on Nov. 16, 2026 in Diseases — General

Ulcerative Colitis Drug Shows Remission Gains

OD-001, a first-in-class RIPK2 scaffolding inhibitor, significantly improved clinical remission in adults with moderately to severely active ulcerative colitis in a phase 2a trial. Results were presented at United European Gastroenterology Week.

Why it matters

Patients in the trial had inadequate responses or intolerances to conventional or advanced therapies, so an effective new option would address an unmet need. The results support moving OD-001 into a larger phase 2b program.

In the phase 2a trial, 27% of patients on the 20 mg twice-daily dose reached clinical remission at 12 weeks, with the primary endpoint met at P < .001. Results from a larger population and longer follow-up have not yet been reported.

The players

Odyssey Therapeutics

Odyssey Therapeutics is the company developing OD-001 as a first-in-class RIPK2 scaffolding inhibitor.

Bruce E. Sands

Bruce E. Sands is a gastroenterologist affiliated with the Icahn School of Medicine at Mount Sinai who was the lead investigator on the trial.

The details

In a trial enrolling adults aged 18 to 75, OD-001 met its primary endpoint of change in modified Mayo Clinic Score from baseline to 12 weeks in both parts of the study and combined. Symptomatic remission appeared as early as week 2, and no significant adverse events were reported; after 12 weeks, patients moved to vedolizumab under standard care.

Timeline

  1. Week 2: Symptomatic remission first observed in trial patients.

  2. 12 weeks: Primary endpoint assessed, with 27% remission in the 20 mg group.

  3. November 12, 2026: Results presented at United European Gastroenterology Week.

Health Landscape

OD-001 is being developed as both a monotherapy and in combination with vedolizumab, an established biologic used in ulcerative colitis. That positioning places the candidate alongside existing advanced therapies rather than in a separate treatment category.

For people with moderately to severely active ulcerative colitis who have not responded well to existing treatments, an effective new oral option could change treatment choices. Any future availability depends on the outcome of the phase 2b program.

The takeaway

Patients with ulcerative colitis who have struggled with conventional or advanced therapies may eventually have a new option, though the drug is still in clinical development. The phase 2b results will be the next key test.

What happens next

OD-001 is moving into a phase 2b development program, both as a monotherapy and in combination with vedolizumab.

Further reading

For related coverage, see Diseases — General.

Source note: This article includes information reported by Healio.